Abstract BACKGROUND: Despite recent advance in conventional cancer therapies including surgery, radiotherapy, chemotherapy, and immunotherapy to reduce tumor size, unfortunately cancer mortality and metastatic cancer incidence remain high. Along with a deeper understanding of stem cell biology, cancer stem cell (CSC) is important in targeted cancer therapy. Herein, we review representative patents using not only normal stem cells as therapeutics themselves or delivery vehicles, but also CSCs as targets for anti-cancer strategy.
Introduction
Cancer, a major threat to public health around the world, is the second leading cause of mortality after ischemic heart disease and stroke [1] . It is characterized by highly complex pathogenesis associated with proliferation, apoptotic resistance, inflammation, neovascularization, invasion, and metastasis under complex circumstances involving tumor cells themselves and host-tumor cell interactions [2] [3] [4] . Despite tremendous impact on health worldwide, progress in cancer treatment has been slow. Only 50% of newly diagnosed cancers could be cured [5] . For this reason, there is an increasing interest in potential anti-cancer strategies including surgery, radiation, and drugs. Tremendous progress has recently been made in understanding the basic biology and therapeutic potential of using stem cells against a variety of disease states. Thus, the concept of using stem cells for treating various diseases is of considerable importance in cancer research.
Stem cells are found in multi-cellular organisms. They are characterized by a specific function with abilities to renew themselves through mitotic cell division while maintaining undifferentiated state to differentiate into multilineages [6, 7] . Different stem cell types have been investigated in both pre-clinical and clinical applications, including embryonic stem cells (ESCs) isolated from the inner cell mass of human blastocysts [8] , mesenchymal stem cells (MSCs) isolated from adult tissues, and induced pluripotent stem (iPS) cells that are reprogrammed from adult somatic cells for pluripotency [9] . ESCs have selfrenewal capacity, pluripotency, and differentiation into various cell lineages for cellular therapy [7, 10, 11] . As a type of multipotent stem cell, MSCs can be isolated from different tissues including adipose tissue, skeletal muscle, umbilical cord blood, and bone marrow [12] . It has been shown that MSCs possess high differentiation ability to various cell types such as adipocytes, osteocytes, and chondrocytes [13, 14] . Currently, MSCs are the most commonly used cells in regenerative medicine in preclinical and clinical applications with several advantages, including easy isolation, high plasticity, safety, and exemption from ethical controversy [15] [16] [17] . Meanwhile, iPS cells are produced through somatic cell reprogramming by introduction of transcription factors (OCT4, SOX2, KLF4, and C-MYC) associated with pluripotency to reverse its condition to embryonic stage [18, 19] . iPSCs are able to self-renew and maintain differentiation potential into any cell type. These characteristics of iPSCs are almost similar to ESCs [20] . Due to lack of ethical issues and safety concerns on transplantation rejection [18, 21] , iPS cells could become a prominent subject in modern regenerative medicine research era.
Patent law for protection of intellectual property is very important in promoting technical innovation and supporting dissemination of creative products. For this, an invention should satisfy adequate requirements for novelty, inventiveness, industrial applicability, and adequate disclosure. After an inventor receives exclusive rights to gain private profit from his invention for a limited time period, he/she can disclose public disclosure of his invention so that anyone can make this new knowledge and develop the technology [22] . In this review, we examined representative patents, which are important for the analysis of recent stem cell research from academic science to industrial innovation, of using cancer stem cells (CSCs) as targets for anti-cancer strategy and using normal stem cells as therapeutic approaches. Table 1 , potential target diseases for stem cell-based therapy include neurodegenerative disorders, diabetes, and diseases of the liver and heart [32, 33] . Neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis result from massive loss of several types of neural cells, leading to nervous system dysfunction [34] . Despite decades of research, unfortunately effective therapies do not exist for them, resulting in growing interest in stem cell therapies as attractive options for differentiation into functional neurons and/or symptom relief [35] . The use of MSC therapy for the treatment of central nervous system disorders including Parkinson's disease, Alzheimer's disease, and ischemic injury has been given by Mironov in a patent published in 2009 (US20090214484 [36] ). In another patent, the role of MSCs for treating amyotrophic lateral sclerosis was provided (US20070253931 [37] ). Stem cells are also considered as promising therapeutic options for advanced diabetes mellitus causing substantial morbidity and mortality [38] . The invention presented by Riordan and Ichim (US20080260703 [39] ) showed that stem cells could be used for treating insulin resistance and diabetes through anti-inflammatory activity and regeneration of insulin producing cells. Atala et al. have also published the regeneration of pancreatic islets by amniotic fluid stem cell therapy (US20070031384 [40] ). In addition, a patent published by Lee and Kim (EP3020405 [41] ) in 2017 is related to prevention of liver fibrosis or liver cirrhosis with MSCs. Another study has exploited MSCs and immunocytes as effective therapeutics for treatment of liver failure (US20160074437 [42] [43] ). The invention disclosure by Franco (US20050214260 [44] ) has provided the role of combination adult stem cells and growth factor for treatment of acute and chronic cardiomyopathy.
Cancer and anti-cancer strategy
Cancer statistics estimated that the number of new cancer cases was 1,735,350 with cancer deaths of 609,640 in 2018 in the United States [45] . In addition to genetic factors for cancer risk, environmental (nongenetic) factors including smoking, poor diet, and physical inactivity also increase cancer burden [46] . Cancer can invade surrounding normal tissue throughout the body along with increased expression of several genes involved in cell motility [47] [48] [49] . There have been some therapeutic methods such as surgery, radiotherapy, chemotherapy, and immunotherapy for cancer. Along with surgical treatment including local excision of the tumor or involved organs [50] , various forms of chemotherapy and radiotherapy have been used primarily for cancer treatment over the last several decades [51] . Chemotherapeutic agents used in anticancer strategy have various mechanisms, including antioxidation, carcinogen inactivation, antiproliferation, cell cycle arrest, apoptosis induction, and angiogenesis inhibition [52] . However, conventional chemotherapy can exert severe toxicity due to high-dose of anticancer agents, resulting in dose-reduction and subsequent therapeutic resistance [53] . Radiotherapy, also called radiation therapy, uses ionizing radiation with electrically charged particles that deposits energy to destroy cells in the target tissue by causing genetic changes in cancer cells, making them impossible to grow [54] . Cancer immunotherapy has also been used as a successful therapeutic anti-cancer strategy for a broad spectrum of tumors by modifying the host's immune system during initial transformation with the use of vaccines, viral vectors, immune check-point inhibitors, and chimeric antigen receptor-modified T cells [55, 56] . Although all these conventional therapies are still useful in lowering a significant proportion of tumor mass, unfortunately the tumor may recur [53, 57, 58] . Despite progress in understanding cancer biology for early detection and prevention, cancer mortality remained high for the past four decades [45, 59, 60] . For this reason, stem cell research is attracting attention as an anti-cancer strategy.
Use of normal stem cells as anti-cancer therapy 4.1 Normal stem cells as anti-cancer therapeutic agents
Stem cells can be attractive therapeutics for many types of cancer (Table 2 ) since they possess inherent tropism to tumor with the presence of a wide variety of chemokine and cytokine receptors on the stem cell surface that respond to many molecules produced by tumors [61] [62] [63] [64] [65] . In fact, many in vivo studies have shown that stem cells preferentially migrate to tumor sites and incorporate into tumors after intravenous [66] [67] [68] [69] [70] [71] , intraperitoneal [72] , and intracerebral delivery [67] . At first, it has been reported that menstrual blood-derived MSCs have anti-tumor effect for treatment of pancreatic carcinoma both in vivo and in vitro.
Moreover, central involvement of dickkopf-related protein 3 (Dkk3) in this anti-tumor effect has been observed (US20170143764 [73] ). Dkk3 is an antagonist of Wnt signaling pathway involved in major biological processes such as cell fate determination and tumorigenesis. It is known to impact tumor growth, providing a new therapy option for inhibiting cancer proliferation [74, 75] . Transplantation of placental stem cells expressing elevated level of one or more genes such as aminopeptidase regulator of type 1 tumor necrosis factor, leukocyte-derived arginine aminopeptidase, interleukin-6, and transforming growth factor (TGF) beta 2 has been identified as an anti-cancer therapy that can suppress the proliferation and growth of bone-related cancers such as multiple myeloma or chondrosarcoma cells (US9121007 [76] ). Treating a metastatic cancer of the liver by MSCs transplantation has also been reported to be able to restore liver function (WO2017036925 [77] ). In addition, it has been demonstrated that factors secreted by MSCs such as hepatocyte growth factor and keratinocyte growth factor can stimulate or support liver regeneration and inhibit metastatic liver tumor growth or migration [78] . Secretory products of human AT-MSCs such as cytokines, amino acids, and growth factors (transforming growth factor, fibroblast growth factor, insulin-like growth factor) can also prevent or treat diverse type of cancers when AT-MSCs are transplanted (US20120263685 [79] ). MSCs can enhance anti-tumor activity of immunotherapy preferably chimeric antigen receptor T cells that bind specifically to a tumorassociated antigen by modulating the tumor microenvironment which leads to stimulation of immune cells (WO2017167959 [80] ). Successful development of stem cell-mediated anticancer therapy depends on many risk factors, including 
Hermann F, Günther C, Geumann U [80] MSCs elevating anti-tumor immunotherapy with CAR-T cells tumor formation, undesirable biodistribution, and differentiation into unwanted cell type. In spite of stem cellbased medicinal benefits related to anti-cancer therapy, stem cell can also be potential factor contributing to malignant transformation [81] . In animal models, promotion of angiogenesis, tumor growth, and metastasis in colon cancer or osteosarcoma have been reported following injection of human bone marrow mesenchymal stem cells (BM-MSCs) [82, 83] . Similar results have been observed for human MSCs by Tsai et al. [84] . It has been recognized that vascular support, immunosuppressive effects, and metastatic support are major mechanisms of stem cell-related tumor promotion [85] [86] [87] . Thus, when injecting these cells to human, potential risk should be carefully considered, including the possibility of stem cell-modulated tumor formation. As mentioned earlier, stem cells possess inherent tropism to tumor with the presence of a wide variety of chemokine and cytokine receptors on the stem cell surface that respond to many molecules produced by tumors [61] [62] [63] [64] [65] . Despite tumor tropism property of stem cells, another risk factor of stem cells is undesirable biodistribution of administered stem cells, resulting in higher risk associated with long-term survival of cells in undesirable tissue [88] . Thus, comprehensive analysis should be conducted to identify unwanted distribution of implanted cells to undesired tissues before clinical development of stem cell-based therapeutics [89] .
Normal stem cells as delivery vehicles
To develop potential agents that can inhibit tumor growth, delivering anti-cancer agents to the site of the tumor is important [22] . Due to their tumor tropism property, stem cells are attractive as delivery vehicles for anti-tumor biological agents [61] [62] [63] [64] [65] . In other words, stem cell-based delivery of anticancer therapeutics can have therapeutic advantages with enhanced tumor specificity involved in tumor homing ability of stem cells without unexpected systemic toxicity of anticancer agents in non-target healthy tissues [22] . Additionally, this can be a good way to maximize therapeutic efficacy of stem cells since many beneficial roles in tissue repair attributed to stem cells may be due to paracrine effects rather than cell differentiation [90] . Due to proven tumor-tropic characteristics of stem cells [62, 70, [91] [92] [93] [94] [95] [96] , tailoring bioengineered stem cells as carriers of anti-cancer agents are widely used (Table 3 and Fig. 1 ). Thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell apoptosis is the most widely used approach for anti-cancer therapy [97] . In the absence (CA2406664 [98] ) or presence (US20120107282 [99] ) of interferon-beta, a potent cytokine that activates immune cells and responds to several diseases [100, 101] , neural stem cells genetically modified to express cytosine deaminase can be used as a cellular and molecular therapy for cancer. As an enzyme found in bacteria and fungi, cytosine deaminase can convert nontoxic prodrug 5-fluorocytosine to cytotoxic agent 5-fluorouracil that is used to treat many types of cancer [102] [103] [104] . Along with remarkable progress of nanotechnology for molecular imaging associated with cancer detection and screening [105] [106] [107] [108] , nanoparticle labeling is widely accepted as a tracking method for BM-MSCs in preclinical and clinical models by MRI. It has been reported that BM-MSCs labeled with monocrystalline iron oxide nanoparticle loaded with nucleic acid sequence encoding a cytosine deaminase can be used for treating and [112] . Thus, TRAIL-engineered stem cells are emerging trends for anti-cancer therapy [113] . MSCs coexpressing TRAIL have excellent anticancer effects (US20140369979 [114] ). A combination of herpes simplex virus thymidine kinase with dodecameric TRAIL has also been studied as anti-cancer strategy [115] . Chemokine (C-C motif) ligand 5 (CCL5) acts to promote immune cell (T cells, macrophages, eosinophils, and basophils) recruitment into inflammatory sites [116] . MSCs that can deliver isolated polynucleotide comprising a promoter element that drives CCL5 expression have been demonstrated as a targeted cancer therapy (US20170000886 [117] ). Vascular endothelial growth factor (VEGF) family of growth factors and its receptors can be fundamental mediators of tumor angiogenesis [118] . It has been shown that MSCs expressing VEGF receptor polypeptide that binds to VEGF and renders it non-functional can inhibit angiogenesis for treatment of cancer (US20170020958 [119] ). Recently, exosomes (packaged vesicles released from cells) containing proteins, lipids, mRNA and miRNA are also considered as promising therapeutic tools for safe and targeted delivery of candidate molecules [120, 121] . Shtam et al. [122] have demonstrated that exosome-delivered siRNA against RAD51 involved in the development, progression and drug resistance of cancer cells [123] can cause cell death of recipient cancer cells. Particularly, exosomes targeted to tumors may be used for treatment of tumor via systemic administration of miRNA. Ohno et al. [124] have shown that exosomes can efficiently deliver let-7a miRNA (a possible tumor suppressor associated with downregulation of RAS/HMGA2) to epidermal growth factor receptor (EGFR)-expressing breast cancer tissue and markedly suppress tumor growth. MicroRNAs play important roles in the regulation of many biological processes, including tissue differentiation and maintenance [11] . They could become a relevant therapeutic target for cancer [125] [126] [127] . Delivery of exogenous microRNAs such as miR-34, miR-192, miR-145, and miR-143 that downregulate cancer-associate proteins by MSCs has been granted a patent as treatment for cancer (WO2016166600 [128] ).
CSCs for targeted cancer therapy

Targeting CSCs via specific markers
It is known that stem cell biology is tightly involved in mechanisms of tumorigenesis. As the role of stem cells in cancer etiology becomes more apparent recently, it has been suggested that oncogenic mutation of normal stem cells may promote the generation of tumor-initiating stem cells, also known as CSCs, ultimately leading to tumor formation [6, [129] [130] [131] [132] . CSCs exhibit self-renewal and multi-lineage differentiation abilities to generate tumors, persist in tumors, and eventually cause relapse or metastasis in secondary organs [133] . Understanding of these characteristics of CSCs has fundamental implications for the development of new anti-cancer therapeutic agents as well as carcinogenesis [134] . Based on CSC theory, Fig. 1 Use of normal stem cells as delivery vehicles for anti-cancer therapeutic agents eradication of cancers, especially most advanced stage cancers, may require targeting of CSCs which have the capacity of extensive proliferation, relapse or metastasis, rather than tumor bulk [135] . As shown in Fig. 2 , this anticancer strategy can selectively kill CSCs, induce differentiation of CSCs, and inhibit the maintenance of stem cell state in order to converse malignant cancers into benign tumors with higher cure rates [130, 136] . Although anticancer treatments can shrink tumors, the remaining tumorigenic cells may drive tumor recurrence if therapy fails to deplete CSCs [53, 57, 58] .
According to this aspect, many studies have determined various markers for CSCs for selective diagnosis or therapy of cancer (Table 4 ). Programmed death-1 (PD-1) is known to be highly expressed in tumor antigen-specific T cells of circulating and tumor-infiltrating lymphocytes in patients with various types of epithelial, hematologic, and other malignancies [137] [138] [139] [140] [141] . It has been reported that siRNA or shRNA that can inhibit the expression of PD-1 (a CSC marker) can be used to kill CSCs in melanoma (EP3130923 [142] ). Several monoclonal antibodies (mAbs) directed against tumor cell-surface antigens are currently used in the therapy of different cancers [143] . CD43, a mucin-like sialoglycoprotein and a leukocyte marker, is present in tumor tissue [144] . The expression of CD44, a transmembrane glycoprotein, has been identified in different types of cancer such as breast, cervical, colon, lung, esophageal, liver, and gastric cancers. CD44 enables communication between CSCs and microenvironment that is important for the invasiveness and metastasis of tumor cells, indicating that it can be an anti-cancer therapeutic target [145, 146] . CD47 has also been found in multiple human tumors [147] . Antibodies targeting CD44 (US8715945 [148] ), CD47 (WO2016057980 [149] ), CD43 (WO2017065493 [150] ) have been studied as therapeutic molecules for selective killing of CSCs. As a marker of cells capable of initiating tumors [151] , disialoganglioside GD2, a sialic acid-containing glycosphingolipid expressed primarily on the cell surface, is highly expressed in a variety of tumors, including neuroblastoma, melanoma, small cell lung cancer, and brain tumors [152] [153] [154] . Since GD2 is expressed in CSCs of epithelial cancer or breast cancer, GD2-binding antibody is reported to be a selective killing agent of CSCs (WO2013130603 [155] ). Epidermal growth factor like domain multiple 6 (EGFL6) is a secreted protein that belongs to the EGF repeat superfamily. The expression of EGFL6 during early fetal development stages of lung, skin, umbilical cord, liver, spleen, and placenta has been reported [156, 157] . It is also highly expressed in some tumors [158, 159] . It has been reported that EGFL6 blocking antibody can restrict CSC growth and delay disease recurrence (WO2014150720 [160] ). Platelet-derived growth factor receptor (PDGFR) is a receptor tyrosine kinase overexpressed in a variety of solid tumors [161] . As a biomarker of CSCs, PDGFR-b can be used to eliminate CSCs (US20140275201 [162] ). Cells expressing leucinerich repeat-containing G-protein coupled receptor 5 (Lgr5) have been considered as CSCs in intestinal cancers [163, 164] . A chimeric antibody that can selectively bind to Lgr5 in caner stem cells and then show cytotoxic activity has been shown to have capacity for selective killing of CSCs (EP2772268 [165] ). As an intestinal stem cell marker, doublecortin and CaM kinase-like-1 (DCAMKL-1) is expressed primarily in quiescent cells in the lower twothirds of intestinal crypt epithelium [166] [167] [168] . DCAMKL-1 has been used as a biomarker of CSCs. It can also inhibit the growth of CSCs (WO2012112156 [169] ). Claudins are a family of tight junction transmembrane proteins [170] . An antibody with ability to bind to claudin-6 can effectively treat or prevent cancer by inhibiting or eliminating CSCs (US20160159901 [171] ). Several studies have demonstrated that aldehyde dehydrogenase 1 (ALDH1), an enzyme responsible for oxidizing aldehydes to carboxylic acids, is a CSC marker in adult cancers [172] [173] [174] [175] . By determining ALDH1 expression, CSCs can be selectively targeted and treated (US8435746 [176] ). Urokinase-type plasminogen activator (uPAR) is overexpressed in several types of human cancer, resulting in enhanced invasion, migration, and metastasis [177] [178] [179] . uPAR is expressed in CSCs, indicating the importance of uPAR ligands as [180] ). Inhibitors of apoptosis (IAP) proteins are often overexpressed in cancers. They are associated with cell death, immunity, inflammation, cell cycle, and migration [181, 182] . Since high-level expression of IAP has been reported in CSCs, IAP inhibitors such as AT-406 and SiRNA can be potentially useful molecules to effectively kill CSCs (WO2011116344 [183] ). ATPbinding cassette, subfamily G, member 2 (ABCG2) is expressed in several human cancers and stem cell populations [184] [185] [186] [187] . CSC populations characterized by expression of ABCG2 and methods of isolating have been reported (US20130244268 [188] ). High expression of ribophorin II (RPN2), part of the N-oligosaccharyltransferase complex, in breast CSCs is associated with tumor metastasis [189] . An endoplasmic reticulum-residing type II transmembrane glycoprotein exostoxin 1 (EXT1) is known to regulate cancer cell stemness in breast cancer cells [190] . These RPN2 (WO2012023345 [191] ) and EXT1 (US20160060634 [192] ) genes can be targeted for the detection and treatment of CSCs. These CSC markers are also useful for developing potential anti-cancer therapeutic strategies using anti-sense oligonucleotides, small molecule inhibitors, and antibodies.
Although there are many reports on CSC markers for targeted cancer therapy, further study is needed to investigate the specificity of developed CSC markers since many CSC markers such as CD29, CD90, CD117, and Oct-4 have also been observed in normal stem cells [193] . Kim and Ryu [194] have also found that several surface markers for sorting CSCs are present in normal tissue cells as well as hESCs, indicating that accurate identification of CSC markers for distinguishing CSCs from normal stem cells is very important to reduce side effects when they are used as therapeutic targets for CSC-specific elimination, not normal stem cells. In addition to identification of CSC-specific markers, multiple surface markers in combination are also helpful for CSC-targeted therapy. 
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Treating cancers by targeting CSCs
As CSC population seems to be an important portion of cancer tissue, targeting CSCs to have a low proliferation rate and a high tumorigenic potential can be an effective strategy to treat cancer [195] . Various compounds have been reported to exert anti-cancer effects by targeting CSCs from cancer tissues (Table 5) . Tigecycline, a glycylcycline antibiotic, could inhibit mitochondrial synthesis of a protein in hematological malignancies [196] . Tigecycline has anti-neoplastic activity against CSCs by decreasing levels of proteins essential for their proliferation (US20120329761 [197] ). Yeh et al. [198] have indicated that a combination of trifluoperazine with either gefitinib or cisplatin can inhibit tumor growth and overcome drug resistance in lung CSCs. A pharmaceutical composition including trifluoperazine and an anti-cancer drug such as gefitinib or cisplatin can eliminate CSCs (US20140294994 [199] ). As one of retinoid agonists with various functions in proliferation, differentiation, immune function, and early embryonic development [200] [201] [202] [203] , a retinoid agonist tamibarotene can act as a CSC proliferation inhibitor and apoptosis inducer (EP3146978 [204] ). Flavonoids as a group of bioactive compounds naturally produced from plants can also reduce the risk of cancer by modulating various mechanisms [205] . Heterosidic flavonoid derivatives can target GSK3b, Akt, FOX03a, and MnSOD signaling pathways and induce apoptosis of CSC of acute myeloid leukaemia (EP2119434 [206] ). It has been shown that several plant phytochemicals (e.g., sulforaphane and resveratrol) can modulate carcinogenesis such as metastasis and angiogenesis [207] [208] [209] . A combination of sulforaphane and resveratrol can also inhibit CSCs (US20160374944 [210] ). Ethylacetate extract of fruiting bodies of Antrodia camphorata (EAC) also exhibits anticancer effects in liver cancer cell lines through induction of apoptosis and inhibition of angiogenesis [211, 212] . This EAC extract is able to restrict CSCs (US20130089627 [213] ). Arsenic compounds have been considered as effective traditional medicine. Among them, sodium meta arsenite has been demonstrated to be useful for cancer treatment [214] . It can eliminate drug-resistant CSCs and mature cancer cells (US20110059186 [215] ). The anticancer role of prolactin, a pituitary hormone regulating several physiological functions [216] , in both breast CSCs and differentiated breast cancer cells has been reported (US8759289 [217] ). Several studies have shown that signal transducer and activator of transcription 3 (STAT3), an oncogene, can promote malignant stem cells in hematopoietic and solid tumors [218] [219] [220] [221] [222] [223] . A novel naphtho class of compound for suppressing aberrant STAT3 activity of CSCs has been reported (WO2009036059 [224] ). In the presence of tyrosine kinase inhibitor as an anti-cancer agent [225] , a STAT5 antagonist thiazolidinedione can eliminate hematologic CSCs in vivo (WO2014068397 [226] ). High mobility group A1 (HMGA1) oncogene is enriched in normal stem cells and poorly differentiated tumors [227] . Inhibiting agent of HMGA1 (US9545417 [228] ) is a selective killer of CSCs in ovarian cancer, pancreatic cancer, breast cancer, and colorectal cancer. Cancer cells rely heavily on glycolysis to meet glucose demand as an energy source through upregulation of glucose transporters [229] . Disruption of normal Ca 2? signaling which plays a fundamental role in cellular physiology such as cell cycle control, autophagy, cell motility, and apoptosis has also been implicated in the development of malignant phenotypes [230, 231] . Similarly, a combination of glucose uptake inhibitor (2-deoxy glucose) and calcium pump inhibitor (caloxin or ni fedipine) has been found to have potential to inhibit CSC (WO2016068600 [232] ). MicroRNAs are single stranded molecules of about 22 nucleotides that can regulate gene expression by targeting mRNA for degradation [125, 233] . Among them, microRNA-145 (miR145) has been demonstrated to be able to induce CSC differentiation through down-regulation of transcription factors essential for maintaining pluripotency [234] . In addition, inhibition of CSC-like properties and chemoradio-resistant properties has been observed after delivering miR145 to cancer cells (US8846633 [235] ). Oncolytic virus has been recognized as a therapeutic reagent for killing cancer cells without harming normal tissues [236] . An oncolytic herpes virus (US8703120 [237] ) and an oncolytic virus having a recombinant binding domain specific for tumor stem cell marker CD133 (US20140065694 [238] ) for treating a subject having CSC have been demonstrated.
Conclusion
All conventional cancer therapies including surgery, radiotherapy, chemotherapy, and immunotherapy are widely used in many hospitals. They are still useful for reducing the size of primary tumor and preventing metastasis. Unfortunately, cancer mortality is still high despite efforts and progress in understanding of cancer biology. Under these circumstances, stem cell-based technology is an exciting and rapidly developing field. Regenerative cell therapy is considered an effective anticancer treatment by promoting organ repair and regeneration via paracrine mechanisms or differentiation into native tissues [239] , although there are current challenges and potential risks involved in stem cell-modulated tumor formation and bio-distribution of stem cells in undesired tissues. In addition to stem cell transplantation as a therapeutic option, stem cell-mediated targeted drug-delivery systems have also been proposed in an effort to reduce undesirable side effects in non-target healthy tissues. A thorough understanding of the CSC concept as a potential target for anti-cancer therapy is very important to obtain improved clinical outcome through successful targeting of cancer. It has led us to a change in thinking about effective CSC-directed anti-cancer strategy since CSCs are closely related to the development of cancer. In recent years, a lot of researchers are in agreement that CSC-targeted approach is a promising tool in cancer treatments, leading them to study CSC-specific markers for identification and selective eradication of CSCs. Many studies concerning different uses of stem cells for the struggle against cancer have been conducted. This review is useful to understand the current status of normal stem cells as therapeutic candidates and CSCs as anti-cancer targets. It also suggests future direction for better anti-cancer strategy without major side effects despite current challenges associated with identification of more specific CSC marker distinguishing CSCs from normal stem cells and mature cancer cells since they share many common features.
